Last reviewed · How we verify
Cenobamate Oral Suspension Fed
Cenobamate Oral Suspension Fed is a Small molecule drug developed by SK Life Science, Inc.. It is currently in Phase 1 development. Also known as: YKP3089.
At a glance
| Generic name | Cenobamate Oral Suspension Fed |
|---|---|
| Also known as | YKP3089 |
| Sponsor | SK Life Science, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cenobamate Oral Suspension Fed CI brief — competitive landscape report
- Cenobamate Oral Suspension Fed updates RSS · CI watch RSS
- SK Life Science, Inc. portfolio CI
Frequently asked questions about Cenobamate Oral Suspension Fed
What is Cenobamate Oral Suspension Fed?
Cenobamate Oral Suspension Fed is a Small molecule drug developed by SK Life Science, Inc..
Who makes Cenobamate Oral Suspension Fed?
Cenobamate Oral Suspension Fed is developed by SK Life Science, Inc. (see full SK Life Science, Inc. pipeline at /company/sk-life-science-inc).
Is Cenobamate Oral Suspension Fed also known as anything else?
Cenobamate Oral Suspension Fed is also known as YKP3089.
What development phase is Cenobamate Oral Suspension Fed in?
Cenobamate Oral Suspension Fed is in Phase 1.
Related
- Manufacturer: SK Life Science, Inc. — full pipeline
- Also known as: YKP3089
- Compare: Cenobamate Oral Suspension Fed vs similar drugs
- Pricing: Cenobamate Oral Suspension Fed cost, discount & access